Gapping up
In reaction to strong earnings/guidance:
- LX +5.4%, MANU +2.5%
Select China related names showing strength:
- CMCM +3.6%, JD +1.2%, BIDU +1%, BABA +0.9%, WB +0.8%
Other news:
- KRTX +83.5% (announces results from Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia)
- MTEM +13.5% (Molecular Templates & Vertex Pharmaceuticals (VRTX) enter into strategic research collaboration)
- DRNA +8.8% (Dicerna Pharmaceuticals and Novo Nordisk (NVO) announce agreement to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases using Dicerna's proprietary GalXC RNAi platform technology.)
- YNDX +6% (authorizes repurchase of up to $300 mln worth of Class A shares)
- EIDX +5.4% (Eidos Therapeutics and BridgeBio Pharma (BBIO) report Phase 2 Open Label Extension suggesting long-term tolerability of AG10)
- AXGT +2.1% (FDA has granted orphan drug designation for the Company's investigational gene therapy, AXO-AAV-GM1, for the treatment of GM1 gangliosidosis)
- F +1.3% (Announces electric Mustang SUV)
Analyst comments:
- N/A